Adaptive enrichment designs for confirmatory trials

After an overview of the Food and Drugs Administration's 2012 draft guidance on enrichment strategies for clinical trials to support drug/biologic approval, we describe subsequent advances in adaptive enrichment designs in this direction. We also provide a concrete application in the enrichment design of the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution 3 trial comparing a new endovascular treatment with standard of care for ischemic stroke patients.

[1]  A. Demchuk,et al.  Thrombectomy within 8 hours after symptom onset in ischemic stroke. , 2015, The New England journal of medicine.

[2]  Deepak L. Bhatt,et al.  Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. , 2015, The New England journal of medicine.

[3]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[4]  Tze Leung Lai,et al.  Power, sample size and adaptation considerations in the design of group sequential clinical trials , 2003 .

[5]  Scott Hamilton,et al.  A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3) , 2017, International journal of stroke : official journal of the International Stroke Society.

[6]  Jay Bartroff,et al.  Sequential Experimentation in Clinical Trials , 2013 .

[7]  T. Lai.  Adaptive treatment allocation and the multi-armed bandit problem , 1987 .

[8]  M. Krause,et al.  Endovascular therapy for ischemic stroke with perfusion-imaging selection. , 2015, The New England journal of medicine.

[9]  Deepak L. Bhatt,et al.  Adaptive Designs for Clinical Trials. , 2016, The New England journal of medicine.

[10]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[11]  Hester F. Lingsma,et al.  A randomized trial of intraarterial treatment for acute ischemic stroke. , 2015, The New England journal of medicine.

[12]  Adnan H Siddiqui,et al.  Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis. , 2016, JAMA.

[13]  N. Simon,et al.  Adaptive enrichment designs for clinical trials. , 2013, Biostatistics.

[14]  Jay Bartroff,et al.  Efficient adaptive designs with mid‐course sample size adjustment in clinical trials , 2008, Statistics in medicine.

[15]  Tze Leung Lai,et al.  Adaptive choice of patient subgroup for comparing two treatments. , 2014, Contemporary clinical trials.

[16]  A. Rai,et al.  Imaging-Based Endovascular Therapy for Acute Ischemic Stroke due to Proximal Intracranial Anterior Circulation Occlusion Treated Beyond 8 Hours From Time Last Seen Well: Retrospective Multicenter Analysis of 237 Consecutive Patients , 2011, Stroke.

[17]  A. Demchuk,et al.  Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging , 2018, The New England journal of medicine.

[18]  Cyrus Mehta,et al.  Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints , 2014, Statistics in medicine.

[19]  Michael D Hill,et al.  Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. , 2013, The New England journal of medicine.

[20]  Olav Jansen,et al.  Diffusion-weighted imaging or computerized tomography perfusion assessment with clinical mismatch in the triage of wake up and late presenting strokes undergoing neurointervention with Trevo (DAWN) trial methods , 2017, International journal of stroke : official journal of the International Stroke Society.

[21]  Christopher Jennison,et al.  Adaptive and nonadaptive group sequential tests , 2006 .

[22]  Scott Hamilton,et al.  Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study , 2006, Annals of neurology.

[23]  Tze Leung Lai,et al.  Efficient Adaptive Randomization and Stopping Rules in Multi-arm Clinical Trials for Testing a New Treatment , 2012, Sequential analysis.

[24]  M. Chen,et al.  Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct , 2018, The New England journal of medicine.

[25]  Olivia Yueh-Wen Liao,et al.  Group sequential designs for developing and testing biomarker-guided personalized therapies in comparative effectiveness research. , 2013, Contemporary clinical trials.

[26]  T. Lai,et al.  Power of an Adaptive Trial Design for Endovascular Stroke Studies: Simulations Using IMS (Interventional Management of Stroke) III Data , 2016, Stroke.

[27]  Manabu Inoue,et al.  MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study , 2012, The Lancet Neurology.

[28]  Tze Leung Lai,et al.  Clinical trial designs for testing biomarker-based personalized therapies , 2012, Clinical trials.

[29]  Michela Ponzio,et al.  Endovascular treatment for acute ischemic stroke. , 2013, The New England journal of medicine.

[30]  H. Diener,et al.  Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. , 2015, The New England journal of medicine.

[31]  Eric E. Smith,et al.  Randomized assessment of rapid endovascular treatment of ischemic stroke. , 2015, The New England journal of medicine.

[32]  H. Robbins,et al.  Asymptotically efficient adaptive allocation rules , 1985 .

[33]  Tze Leung Lai,et al.  Adaptive design of confirmatory trials: Advances and challenges. , 2015, Contemporary clinical trials.

[34]  Bradley P. Carlin,et al.  Bayesian Adaptive Methods for Clinical Trials , 2010 .

[35]  Edward S. Kim,et al.  Bayesian adaptive design for targeted therapy development in lung cancer — a step toward personalized medicine , 2008, Clinical trials.